AI assistant
Adaptimmune Therapeutics PLC — Director's Dealing 2022
May 5, 2022
34721_dirs_2022-05-04_a42e9ca3-71d5-4a76-969f-d40f477d181c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2022-05-04
Reporting Person: Brewer Joanna Elizabeth (Chief Scientific Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-05-04 | Option to purchase Ordinary Shares | $0.30 | A | 333792 | Acquired | 2032-05-04 | Ordinary Shares (333792) | Direct |
| 2022-05-04 | Option to purchase Ordinary Shares | $0.0013 | A | 223512 | Acquired | 2032-05-04 | Ordinary Shares (223512) | Direct |
Footnotes
F1: The exercise price was converted from GBP0.24 based on an exchange rate of U.S.$1.2513 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2: Exercisable as to 83,448 Ordinary Shares on May 4, 2023 and will be exercisable as to the remainder in monthly installments of 6,954 Ordinary Shares on the fourth of each month from June 4, 2023 through May 4, 2026.
F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.2513 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4: Exercisable as to 55,878 Ordinary Shares on May 4, 2023 and will be exercisable as to the remainder in annual installments of 55,878 Ordinary Shares on the fourth of each May from May 4, 2024 through May 4, 2026.